No association of the serotonin transporter polymorphisms 5-HTTLPR and rs25531 with schizophrenia or neurocognition

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 153, Issue 5, 2010, Pages 1115-1117

  Konneker, Thomas I ^a   Crowley, James J ^a   Quackenbush, Corey R ^a   Keefe, Richard S E ^b   Perkins, Diana O ^a   Stroup, T Scott ^a   Lieberman, Jeffrey A ^c   Van Den Oord, Edwin ^d   Sullivan, Patrick F ^a,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5 HTTLPR; Association study; Neurocognition; rs25531; Schizophrenia

Indexed keywords

SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, HUMAN;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOMATOLOGY; WORKING MEMORY; ADOLESCENT; AGED; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COGNITION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 77954366969     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31077     Document Type: Article

References (9)

1. Delbruck SJ, Wendel B, Grunewald I, Sander T, Morris-Rosendahl D, Crocq MA, Berrettini WH, Hoehe MR. 1997.Anovel allelic variant of the human serotonin transporter gene regulatory polymorphism. Cytogenet Cell Genet 79:214-220.
2. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, et al. 2006. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78:815-826.
3. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer H, Green MF, Miller DD, Canive J, et al. 2006. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31:2033-2046.
4. Lesch K-P, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL. 1996. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531.
5. Lieberman JA. 2006. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 63:1069-1072.
6. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, Griem A, Kovacs M, Ott J, Merikangas KR. 2009. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: A meta-analysis. JAMA 301:2462-2471.
7. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. 2003. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull 29:15-31.
8. Sullivan PF, Keefe RSE, Lange LA, Lange EM, Stroup TS, Lieberman JA, Maness PF. 2007. NCAM1 and neurocognition in schizophrenia. Biol Psychiatry 61:902-910.
9. Sullivan PF, Lin D, Tzeng JY, van den Oord EJCG, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, et al. 2008. Genomewide association for schizophrenia in the CATIE study: Results of Stage 1. Mol Psychiatry 13:570-584.